Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Account Payables (2016 - 2025)

Voyager Therapeutics' Change in Account Payables history spans 11 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 246.53% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $1.0 million, down 57.48%, while the annual FY2025 figure was $1.0 million, 57.48% down from the prior year.
  • Change in Account Payables for Q4 2025 was $2.9 million at Voyager Therapeutics, up from $312000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.0 million in Q1 2024 and bottomed at -$5.0 million in Q2 2024.
  • The 5-year median for Change in Account Payables is $215500.0 (2022), against an average of $218950.0.
  • The largest annual shift saw Change in Account Payables soared 6927.78% in 2022 before it plummeted 11427.78% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$18000.0 in 2021, then skyrocketed by 6927.78% to $1.2 million in 2022, then crashed by 235.56% to -$1.7 million in 2023, then surged by 150.18% to $836000.0 in 2024, then skyrocketed by 246.53% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Change in Account Payables are $2.9 million (Q4 2025), $312000.0 (Q3 2025), and -$830000.0 (Q2 2025).